Samsrita Labs
17.01
-1.88(-9.95%)
Market Cap₹38.72 Cr
PE Ratio-5.69
Company Performance:
1D-9.95%
1M-5.18%
6M-10.47%
1Y-5.50%
5Y-54.34%
View Company Insightsright
More news about Samsrita Labs
25Oct 25
Samsrita Labs Acquires Cancer Drug Patent, Reports Q2 FY26 Results
Samsrita Labs Limited reported a consolidated loss for Q2 FY26, with a net loss of Rs 454.77 lakhs. The company acquired a cancer drug patent for Rs 2 crores and took a 28.62% stake in QROPS Advisory Services. It raised funds through a preferential issue of equity shares and made financial adjustments including write-offs of advances and provisions for bad debts. Despite current losses, management views recent strategic moves as positioning the company for future growth in the healthcare sector.
 no imag found
08Sept 25
Samsrita Labs Appoints New Company Secretary and Compliance Officer
Samsrita Labs Limited has appointed Mrs. M. Gita Usha Rani as the new Company Secretary and Compliance Officer, effective September 8, 2025. The decision was made during a board meeting on the same date. Mrs. Rani is a qualified Company Secretary with over 8 years of experience in secretarial work. She currently holds no shares in the company and has no relationships with other board directors. The appointment follows existing norms for Key Managerial Personnel and complies with SEBI regulations. The company has informed both BSE Limited and Metropolitan Stock Exchange of India Limited about this development.
 no imag found
28Jul 25
Basaboini Family Acquires 6.6% Stake in Samsrita Labs Through Preferential Allotment
Four members of the Basaboini family have acquired a combined 6.6% stake in Samsrita Labs Limited through a preferential allotment on July 18, 2025. The acquisition involved 15,00,000 shares, with Basaboini Malathi and Mallikarjun Rao Basaboini each acquiring 2.20% stakes, while Mrinalini Basaboini and Mriganayani Basaboini each acquired 1.10% stakes. This acquisition has increased the company's total equity share capital from 1,48,08,706 to 2,27,49,710 shares. The acquirers, who were not part of the promoter group and had no previous holdings, have filed the necessary disclosures under SEBI regulations.
 no imag found
23Jul 25
Samsrita Labs Sees 7.10% Stake Acquisition Through Preferential Allotment
Perla Naga Pattabhi Ravikanth has acquired a 7.10% stake (16,16,001 equity shares) in Samsrita Labs Limited through a preferential allotment on a swap basis. The allotment occurred on July 18, 2025, changing Ravikanth's shareholding from 0 to 16,16,001 shares. This acquisition has triggered disclosure requirements under SEBI regulations. Samsrita Labs is listed on the Metropolitan Stock Exchange of India Limited, and the acquirer is not part of the promoter group.
 no imag found
21Jul 25
Samsrita Labs Limited Allots 33.91 Lakh Equity Shares in Preferential Issue
Samsrita Labs Limited's board approved a preferential allotment of 33.91 lakh equity shares to non-promoters at Rs. 10 per share, raising Rs. 3.39 crore. Four individuals, led by Mallikarjun Rao Basaboini and Basaboini Malathi, acquired a combined 6.56% stake. The company's share capital increased from 1.48 crore to 2.28 crore equity shares, representing a 54.3% expansion. The allotment complies with SEBI regulations and significantly alters the company's ownership structure.
 no imag found
Samsrita Labs
17.01
-1.88
(-9.95%)
1 Year Returns:-5.50%
Industry Peers
Dr. Lal Path Labs
1,355.10
(-1.59%)
Metropolis Healthcare
1,808.60
(-0.84%)
Krsnaa Diagnostics
603.65
(-1.33%)
Suraksha Diagnostic
259.85
(+1.01%)
3B BlackBio DX
1,187.85
(-2.25%)
Sastasundar Ventures
281.00
(-0.35%)